Media
Media
Our latest announcements
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
Regulatory press release
19/12/2025
Hansa Biopharma presenting at 44th Annual J.P. Morgan Healthcare Conference
19/12/2025
Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease
Regulatory press release
16/12/2025
Hansa Biopharma announce changes to strengthen European and International organisation
15/12/2025
Media articles
Insights
The Power of Hope: Redefining Treatment Decisions for Highly Sensitized Kidney Patients
07/08/2025
Collaboration across the continuum of care to improve equity for highly sensitized people in kidney transplantation
17/07/2024
A concerted collaboration to advance treatment options for people living with rare diseases
26/06/2024
Fueling the future: the role of biotech in advancing innovative science and delivering new medicines
02/05/2024
Patients' perspective
Life on tour with chronic kidney disease
“I had always played the guitar and wrote songs but never really did anything with it. Nothing was going to hold me back now! No more excuses… there wasn’t time!”
Patients' perspective
Suspended time: a journey from diagnosis to transplant
"Dialysis may sound simple, but it isn’t, and over the course of his treatment Ron underwent several different kinds, all of which made him feel awful."
